The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis
Open accessAbstract
Importance: Progression independent of relapse activity (PIRA) is the main event responsible for irreversible disability accumulation in relapsing multiple sclerosis (MS). Objective: To investigate clinical and neuroimaging predictors of PIRA at the time of the first demyelinating attack and factors associated with long-term clinical outcomes of people who present with PIRA. Design, Setting, and Participants: This cohort study, conducted from January 1, 1994, to July 31, 2021, included patients with a first demyelinating attack from multiple sclerosis; patients were recruited from 1 study center in Spain. Patients were excluded if they refused to participate, had alternative diagnoses, did not meet protocol requirements, had inconsistent demographic information, or had less than 3 clinical assessments. Exposures: Exposures included (1) clinical and neuroimaging features at the first demyelinating attack and (2) presenting PIRA, ie, confirmed disability accumulation (CDA) in a free-relapse period at any time after symptom onset, within (vs after) the first 5 years of the disease (ie, early/late PIRA), and in the presence (vs absence) of new T2 lesions in the previous 2 years (ie, active/nonactive PIRA). Main Outcomes and Measures: Expanded Disability Status Scale (EDSS) yearly increase rates since the first attack and adjusted hazard ratios (HRs) for predictors of time to PIRA and time to EDSS 6.0. Results: Of the 1128 patients (mean [SD] age, 32.1 [8.3] years; 781 female individuals [69.2%]) included in the study, 277 (25%) developed 1 or more PIRA events at a median (IQR) follow-up time of 7.2 (4.6-12.4) years (for first PIRA). Of all patients with PIRA, 86 of 277 (31%) developed early PIRA, and 73 of 144 (51%) developed active PIRA. Patients with PIRA were slightly older, had more brain lesions, and were more likely to have oligoclonal bands than those without PIRA. Older age at the first attack was the only predictor of PIRA (HR, 1.43; 95% CI, 1.23-1.65; P < .001 for each older decade). Patients with PIRA had steeper EDSS yearly increase rates (0.18; 95% CI, 0.16-0.20 vs 0.04; 95% CI, 0.02-0.05; P < .001) and an 8-fold greater risk of reaching EDSS 6.0 (HR, 7.93; 95% CI, 2.25-27.96; P = .001) than those without PIRA. Early PIRA had steeper EDSS yearly increase rates than late PIRA (0.31; 95% CI, 0.26-0.35 vs 0.13; 95% CI, 0.10-0.16; P < .001) and a 26-fold greater risk of reaching EDSS 6.0 from the first attack (HR, 26.21; 95% CI, 2.26-303.95; P = .009). Conclusions and Relevance: Results of this cohort study suggest that for patients with multiple sclerosis, presenting with PIRA after a first demyelinating event was not uncommon and suggests an unfavorable long-term prognosis, especially if it occurs early in the disease course.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30481-1 · Cited by 1,797
Wattjes, M. P., Ciccarelli, O., Reich, D. S., Banwell, B., de Stefano, N., Enzinger, C., Fazekas, F., Filippi, M., Frederiksen, J., Gasperini, C., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00095-8 · Cited by 674
Self-citationKappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1568 · Cited by 658
Defining high, medium, and low impact prognostic factors for developing multiple sclerosis
Tintore, M., Rovira, À., Río, J., Otero-Romero, S., Arrambide, G., Tur, C., Comabella, M., Nos, C., Arévalo, M. J., Negrotto, L., et al. (2015) · Brain · doi:10.1093/brain/awv105 · Cited by 530
Self-citationDefining secondary progressive multiple sclerosis
Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., et al. (2016) · Brain · doi:10.1093/brain/aww173 · Cited by 415
Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study
Portaccio, E., Bellinvia, A., Fonderico, M., Pastò, L., Razzolini, L., Totaro, R., Spitaleri, D., Lugaresi, A., Cocco, E., Onofrj, M., et al. (2022) · Brain · doi:10.1093/brain/awac111 · Cited by 163
Tintoré, M., Arrambide, G., Otero‐Romero, S., Carbonell‐Mirabent, P., Río, J., Tur, C., Comabella, M., Nos, C., Arévalo, M. J., Anglada, E., et al. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519877810 · Cited by 92
Self-citation
Cited by
Jakimovski, D., Bittner, S., Zivadinov, R., Morrow, S. A., Benedict, R. H., Zipp, F., & Weinstock-Guttman, B. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01473-3 · Cited by 597
Brieva, L., Calles, C., Landete, L., & Oreja-Guevara, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1543649 · Cited by 16
Bruton’s Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment
Greenberg, B. M. (2024) · Neurologic Clinics · doi:10.1016/j.ncl.2023.07.006 · Cited by 10
Metadata
- Authors
- Tur, C., Carbonell-Mirabent, P., Cobo-Calvo, Á., Otero-Romero, S., Arrambide, G., Midaglia, L., Castilló, J., Vidal-Jordana, Á., Rodríguez-Acevedo, B., Zabalza, A., Galán, I., Nos, C., Salerno, A., Auger, C., Pareto, D., Comabella, M., Río, J., Sastre-Garriga, J., Rovira, À., Tintoré, M., & Montalban, X.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2023-02-01
- Volume
- 80
- Issue
- 2
- Pages
- 151
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W4311933194
- Cited by
- 273
- References
- 16
- FWCI
- 30.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.